Background Alpha-methylacyl-CoA racemase (AMACR) is the preferred biomarker for distinguishing malignant from benign glands in prostate biopsies, showing high sensitivity and specificity for prostate cancer. A meta-analysis of immunohistochemistry (IHC) for AMACR is essential to further assess its diagnostic accuracy across diverse sample sources. Methods: A systematic search of databases including MEDLINE, ScienceDirect, ProQuest, Google Scholar, and the Cochrane Library was performed, focusing on studies of AMACR to diagnose prostate cancer, particularly in biopsy samples analyzed through IHC over the last 20 years. Quality of studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, followed by a meta-analysis of regions and subgroups to calculate summary estimates of diagnostic test accuracy. Results: In the final analysis, 37 studies, with a pooled size of 5,898 samples, were included from the examination of 94 full-text papers. Among them, 27 studies with similar sample sources and testing methodologies underwent meta-analysis, yielding a combined sensitivity estimate of 0.90 (95% confidence interval [CI], 0.86 to 0.93) and specificity of 0.91 (95% CI, 0.83 to 0.95), both with significant heterogeneity (p < .01). The region beneath the hierarchical summary receiver operating characteristic curve was 0.95 (95% CI, 0.93 to 0.97), positive likelihood ratio was 9.6 (95% CI, 5.3 to 17.4), negative likelihood ratio was 0.11 (95% CI, 0.08 to 0.15), and diagnostic odds ratio was 88 (95% CI, 42 to 181). Conclusions: Our meta-analysis findings substantiate AMACR as a highly accurate tool for diagnosing prostate cancer, specifically in biopsy samples, via immunohistochemical staining. Further studies involving diverse samples are needed to enhance our understanding of the AMACR diagnostic accuracy in a range of clinical settings.
Citations
Citations to this article as recorded by
ATP binding cassette subfamily D member 1: A highly sensitive diagnostic marker for solid pseudopapillary neoplasm of pancreas in biopsy samples——A multi-institutional study Yuanhao Liu, Junya Peng, Ruizhe He, Xiaowei Xue, Jie Cui, Mengjie Li, Ying-ao Liu, Wanni Xu, Xiaohong Gao, Yingmei Wang, Zhe Zhang, Haizhen Lu, Zhigang Song, Peizhen Hu, Yupei Zhao, Wenze Wang Human Pathology.2026; 174: 106125. CrossRef
Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer Angela Yee, Jim Smith, Rajiv Kumar, Akash Sali, Euan J. Rodger, Aniruddha Chatterjee Cancer and Metastasis Reviews.2026;[Epub] CrossRef
Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity Ya-Ting Wen, Rosario Trijuliamos Manalu, Han-Lin Hsu, Yu-Cheng Kuo, Ruey-Shyang Soong, Feng-Cheng Liu, Maryam Rachmawati Sumitra, Sheng-Liang Huang, Shih-Yu Lee, Sung-Ling Tang, I-Chuan Yen, Hong-Jaan Wang, Bashir Lawal, Alexander T. H. Wu, Hsu-Shan Huang Cells.2026; 15(14): 1314. CrossRef
Sub-Saharan African Prostate Cancer Patient-Derived Cell Lines and High-Throughput Drug Screening: Addressing Ancestry Underrepresentation in Oncobiology Research Carla S. Dos Santos, Ana C. Magalhães, Veronica Fernandes, António Pombinho, Lurdes Torres, Margarida André, Adelaide Sousa, Pedro Sequeira, Daniel Pinto, Cláudia Pereira, Paulo M. Costa, Lúcio Lara Santos, Luisa Pereira Cancers.2026; 18(15): 2452. CrossRef
Prostate Cancer with Pleural Metastasis: A Case Report 金瑶 宋 Journal of Clinical Personalized Medicine.2026; 05(04): 190. CrossRef
Pathogenesis-Guided Biomarker Assessment: A Shift in Prostate Cancer Diagnostics Jessica M. Logan, Victoria Malone, John J. O’Leary, Doug A. Brooks International Journal of Molecular Sciences.2025; 26(24): 11786. CrossRef